Description

Ipamorelin 10 mg — Selective Ghrelin Receptor Agonist for GH Pulse Research

Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue receptor (GHS-R / ghrelin receptor) agonist designed to stimulate pulsatile growth hormone (GH) release. In preclinical research, Ipamorelin has been studied for its highly selective GH-releasing profile, with notably minimal effects on other pituitary hormones such as cortisol, prolactin, or aldosterone — distinguishing it from earlier GH secretagogues that produce broader endocrine activation.

What It Is

• Class: Selective ghrelin receptor (GHS-R) agonist / growth hormone secretagogue
• Concept: Mimics ghrelin signaling at the pituitary to drive pulsatile GH release, with a selectivity profile that minimizes off-target hormonal effects in research models.
• Format: Research-grade synthetic peptide supplied as a lyophilized powder.

Proposed Mechanisms (Preclinical)

Ghrelin Receptor Activation

• Binds the GHS-R1a (ghrelin receptor) on pituitary somatotroph cells.
• Triggers pulsatile GH release through G-protein-coupled signaling pathways.
• Demonstrates high selectivity — research shows minimal cross-activation of cortisol, prolactin, ACTH, or aldosterone pathways at standard research concentrations.

Downstream Endocrine Effects

• Research explores changes in GH pulse amplitude and frequency in animal models.
• Investigations into IGF-1 elevation secondary to stimulated GH release.
• Studies on lean mass markers, body composition, and recovery indices.
• Examination of combined-pathway approaches with GHRH analogs for amplified GH response.

Selected Research Highlights

• Selectivity Profile: Ipamorelin has been characterized for its distinctive lack of significant impact on cortisol, prolactin, and other non-GH endocrine axes, making it a preferred reference compound in selectivity research.
• Combined-Compound Studies: Research has examined synergistic GH release when Ipamorelin is paired with GHRH analogs such as CJC-1295.
• Pharmacokinetic Studies: Investigations into half-life, receptor binding affinity, and dose-response relationships in animal models.
• Body Composition Research: Animal studies examining changes in lean mass, adipose tissue, and recovery markers following GH pathway stimulation.

Chemical & Handling Information

• Type: Synthetic pentapeptide (5-amino-acid sequence)
• Backbone: Aib-His-D-2-Nal-D-Phe-Lys-NH₂ — a pentapeptide designed for selective GHS-R activation (exact sequence per lot specification)
• Appearance: White to off-white lyophilized powder
• Solubility: Reconstitutes readily in bacteriostatic water or sterile saline for laboratory preparation

Specifications

• Peptide: Ipamorelin
• Amount: 10 mg per vial
• Form: Lyophilized powder
• Purity: ≥99% (HPLC); COA per lot available
• Packaging: Sealed glass vials with rubber stopper and aluminum crimp seal, suitable for standard laboratory handling

Storage & Stability

• Store lyophilized vials in a cool, dry place, protected from light.
• Refrigeration or freezing of the lyophilized peptide is recommended for extended stability, in accordance with standard laboratory SOPs.
• After reconstitution, store at 2–8 °C for short-term laboratory use (typically up to 30 days).
• For long-term storage of reconstituted material, aliquot and freeze at −20 °C or below.
• Avoid repeated freeze-thaw cycles, which can degrade peptide integrity.

Research Use Disclaimer

This product is sold strictly for laboratory research use only. Not intended for human or animal consumption. Not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease or condition. Customers are solely responsible for the lawful handling, storage, and use of this product in accordance with all applicable laws and regulations.